These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 17471861)
1. [Myth and realities of antifibrotic medication]. Kershenobich D Rev Gastroenterol Mex; 2005 Nov; 70 Suppl 3():60-1. PubMed ID: 17471861 [No Abstract] [Full Text] [Related]
2. Antifibrotic therapy of liver cirrhosis, with special reference to primary biliary cirrhosis: promises and limitations. Jansen PL Neth J Med; 1992 Apr; 40(3-4):209-14. PubMed ID: 1603214 [No Abstract] [Full Text] [Related]
3. [Site of liver fibrosis and an attempt to control it]. Takahashi T; Fujisawa K; Tanaka T; Kubo T; Kimura A Saishin Igaku; 1969 Jan; 24(1):181-3. PubMed ID: 5777188 [No Abstract] [Full Text] [Related]
4. What is the potential role of antifibrotic agents for the treatment of liver disease? Schnabl B; Scholten D; Brenner DA Nat Clin Pract Gastroenterol Hepatol; 2008 Sep; 5(9):496-7. PubMed ID: 18628735 [No Abstract] [Full Text] [Related]
5. Fibrogenesis in cirrhosis. Potential for therapeutic intervention. Rojkind M Pharmacol Ther; 1992; 53(1):81-104. PubMed ID: 1641403 [TBL] [Abstract][Full Text] [Related]
6. Hepatobiliary and pancreatic: cirrhosis secondary to hepatic sarcoidosis. Malhotra A; Naniwadekar A; Sood G J Gastroenterol Hepatol; 2008 Dec; 23(12):1942. PubMed ID: 19120880 [No Abstract] [Full Text] [Related]
7. Viral hepatitis after liver transplantation. Which immunosuppressive drugs should be recommended? Ciesek S; Manns MP; Wedemeyer H Minerva Gastroenterol Dietol; 2007 Dec; 53(4):337-50. PubMed ID: 18043552 [TBL] [Abstract][Full Text] [Related]
8. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Popov Y; Schuppan D Hepatology; 2009 Oct; 50(4):1294-306. PubMed ID: 19711424 [TBL] [Abstract][Full Text] [Related]
9. Cirrhosis reversal: a duel between dogma and myth. Desmet VJ; Roskams T J Hepatol; 2004 May; 40(5):860-7. PubMed ID: 15094237 [No Abstract] [Full Text] [Related]
10. [Immunosuppressive agents in treatment of liver cirrhosis: personal experience]. Laurent J; Mauuary G; Bas M; Vautrin D; Drouin P; Gaucher P; Heully F Acta Gastroenterol Belg; 1968 Nov; 31(11):780-5. PubMed ID: 5746039 [No Abstract] [Full Text] [Related]
11. Regression of cirrhosis of the liver detected by elastiometry. Mössner BK; Biagini M; Pedersen C; Christensen PB Scand J Gastroenterol; 2008; 43(11):1401-2. PubMed ID: 18615357 [No Abstract] [Full Text] [Related]
13. Attenuation of hepatic fibrosis through captopril and enalapril in the livers of bile duct ligated rats. Karimian G; Mohammadi-Karakani A; Sotoudeh M; Ghazi-Khansari M; Ghobadi G; Shakiba B Biomed Pharmacother; 2008 Jun; 62(5):312-6. PubMed ID: 18191530 [TBL] [Abstract][Full Text] [Related]
14. Novel therapeutic options in the inflammatory bowel disease world. Noble A; Baldassano R; Mamula P Dig Liver Dis; 2008 Jan; 40(1):22-31. PubMed ID: 17988966 [TBL] [Abstract][Full Text] [Related]